Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Kavanaugh, CA
Bart Kavanaugh, Manhattan Beach, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100169129 | SYSTEM FOR FUNDING, ANALYZING AND MANAGING LIFE INSURANCE POLICIES FUNDED WITH ANNUITIES - The invention relates to a program that administers a method of funding life insurance policies using annuities that are purchased at least in part using borrowed money, using business and trust structures to reduce and/or eliminate tax. This investing can be done either directly by the policy or through the trust and/or other business entity. As an internal investment of the insurance policy the income generated by the annuity and the inside build-up are non-income taxable to the owner of the policy. The resulting death benefits will also be non-income taxable to the beneficiary. | 07-01-2010 |
Michael Kavanaugh, Orinda, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090246208 | METHODS FOR PREVENTING AND TREATING CANCER METASTASIS AND BONE LOSS ASSOCIATED WITH CANCER METASTASIS - Methods for preventing and treating osteolysis, cancer metastasis and bone loss associated with cancer metastasis by administering an M-CSF-antagonist in combination with a therapeutic agent to a subject are provided. | 10-01-2009 |
Michael Kavanaugh, Mill Valley, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090074776 | Human FGF-21 gene and gene expression products - This invention relates to human fibroblast growth factor (hF-GF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21. | 03-19-2009 |
Michael Kavanaugh, Emeryville, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100099123 | Soluble Human M-CSF Receptor and Uses Thereof - Soluble human M-CSF receptor is provided, along with pharmaceutical compositions containing such receptor, kits containing a pharmaceutical composition, and methods of diagnosing and treating diseases and disorders associated with M-CSF such as bone loss in a subject afflicted with an osteolytic disease. | 04-22-2010 |
Richard Thomas Kavanaugh, Encinitas, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090141707 | SYSTEMS AND METHODS FOR PROVIDING EMERGENCY SERVICE TRUST IN PACKET DATA NETWORKS - A method and apparatus for providing in a packet data telecommunication network serving one or more end terminals and/or Mobile Stations (MSs), a method for establishing, managing, modifying, and terminating an End-to-End (E2E) Emergency Service (ES) Chain-of-Trust (CoT) from an Access Serving Network (ASN) and Connectivity Service Network (CSN) to a PSAP, PSAP proxy, or PSAP (i.e. PSTN) gateway that results in the creation of a trust relationship amongst the components in the established ES CoT necessary to allow or validate the granting of any unauthenticated or unprovisioned ES network access and ES operation establishment, modification, and termination requests from amongst the components in an ES CoT to assist a particular terminal/MS or ES network component attempting to establish an ES session between the ES user agent of the terminal/MS and a serving PSAP. | 06-04-2009 |
| 20100199290 | SYSTEM AND METHOD FOR MULTIFUNCTION DEVICE ENUMERATION - Disclosed are systems and methods for controlling the enumeration of a multifunction peripheral device on a host computer. A multifunction peripheral device may include a generic and non-generic functional units connected to a host interface. The device may store in its non-volatile memory one or more drivers for the non-generic functional unit. The peripheral device may further include a controller for controlling the order in which the generic and non-generic functional units are exposed to and enumerated on the host system. The controller may include a switch operable to switch on and off the generic and non-generic functional units thereby controlling the order in which these units are exposed to and enumerated on the host system. | 08-05-2010 |
| 20100216524 | APPARATUS PROVIDING PLURAL WIRELESS TRANSCEIVERS WITHIN A DESIRED POWER BUDGET AND ASSOCIATED METHOD - The present invention provides an apparatus providing plural wireless transceivers within a desired power budget and associated methods. A plurality of wireless communication modules, each having a lower-power state and a higher-power state are provided, drawing power from a common source. Arbitration is performed to control which of the plurality of wireless communication modules are in the higher-power state, thereby controlling total power delivered by the power source to the plurality of wireless communication modules. | 08-26-2010 |
| 20110103384 | ROUTING DEVICE AND METHOD OF CONFIGURATION FOR NETWORK NAME RESOLUTION OF SAME - There is provided a routing device configured for operatively interconnecting a first digital data network (DDN) and a second DDN. The routing device comprises a first and second interface for operative connection with the respective first and second DDN and for transferring data packets associated with the first and second DDN. The routing device further comprises a processing system for processing the data packets and for transferring the data packets between the first interface and the second interface based upon address information encoded in the data packets. The processing system is configured with a routing device designation for identifying the routing device and a network address associated with the first DDN. Upon activation of the routing device, the processing system returns the network address in response to a network name resolution request for the routing device designation encoded in one or more first data packets characterized by one or more predetermined network protocols received from the first DDN. | 05-05-2011 |
William M. Kavanaugh, Emeryville, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090324604 | M-csf specific monoclonal antibody and uses thereof - M-CSF-specific antibody RX1 is provided, along with pharmaceutical compositions containing antibody RX1, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease. | 12-31-2009 |
William M. Kavanaugh, Orinda, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20080233118 | Uses Of Antibody To M-Csf - Methods of using M-CSF antibodies to treat macrophage-associated diseases including atherosclerosis and HIV are provided. | 09-25-2008 |
| 20100092464 | M-CSF-Specific Monoclonal Antibody and Uses Thereof - M-CSF-specific RX1-based or RX-I derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in or remodeling in a subject afflicted with an osteoblastic or osteolytic disease. | 04-15-2010 |
| 20110091451 | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis - M-CSF antagonists are used to prepare compositions, including pharmaceutical compositions, for preventing or treating cancer metastasis and/or bone loss associated with cancer metastasis in a mammal. | 04-21-2011 |
W. Michael Kavanaugh, Mill Valley, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20080200378 | KGF polypeptide compositions - Compositions comprising keratinocyte growth factor (KGF) polypeptides and methods of using the same are described. The KGF polypeptides of the present invention display enhanced bioactivity relative to full-length KGF | 08-21-2008 |
| 20090221504 | DOSE OF AN ANGIOGENIC FACTOR AND METHOD OF ADMINISTERING TO IMPROVE MYOCARDIAL BLOOD FLOW - The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis. In another aspect, the present invention is directed to a method for treating a patient for coronary artery disease, comprising administering directly into the myocardium in an area of need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent. In yet another aspect, the present invention is directed to a method for treating a patient for a myocardial infarction, comprising administering directly into the myocardium in an area in need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent. | 09-03-2009 |
W. Michael Kavanaugh, Marin, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090170776 | ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF AND METHOD OF ADMINISTERING - The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 μg/kg to 36 μg/kg of an FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14 or an angiogenically active fragment or mutein thereof. In yet another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof. | 07-02-2009 |